Key Developments: Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

22 Oct 2014
Price Change (% chg)

¥51 (+3.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Co Ltd updates takeover bid offering to Ambit Biosciences
Monday, 13 Oct 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:Says began takeover bid offering to Ambit Biosciences through U.S-based subsidiary Charge Acquisition Corp. at price of $15 per share on Oct. 10 (eastern time of U.S).Says the deadline of takeover bid is planned on Nov. 10 (eastern time of U.S).Plan disclosed on Sep. 29.  Full Article

Perosphere and Daiichi Sankyo Co Ltd enter into clinical trial collaboration agreement for Phase 3 studies of PER977
Monday, 6 Oct 2014 11:50am EDT 

Perosphere and Daiichi Sankyo Co Ltd:Enter into Clinical Trial Collaboration Agreement for Phase 3 Studies of PER977 to Investigate Reversal of the Anticoagulant Activity of the Investigational Factor Xa-Inhibitor Edoxaban.Perosphere Inc. entered into third clinical trial collaboration agreement with Daiichi Sankyo, Inc. to study PER977, Perosphere's investigational anticoagulant reversal agent, in phase 3 registration studies with edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.  Full Article

Daiichi Sankyo Co Ltd to fully acquire Ambit Biosciences
Sunday, 28 Sep 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:To fully acquire Ambit Biosciences through a newly founded subsidiary at $315 million , or up to $410 million including additional consideration.  Full Article

Daiichi Sankyo Co Ltd receives approval for additional indications of Lixiana (edoxaban) in Japan
Friday, 26 Sep 2014 07:03am EDT 

Daiichi Sankyo Co Ltd:Says it received approval from the Ministry of Health, Labour and Welfare in Japan for LIXIANA for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE).Says it has also filed for approval of once-daily edoxaban in both the U.S. and EU for the prevention of stroke in NVAF and for symptomatic VTE in patients DVT and/or pulmonary embolism (PE).(2, 3).  Full Article

R&I affirms Daiichi Sankyo Co Ltd's rating at "AA" and announces negative outlook
Monday, 22 Sep 2014 02:00am EDT 

Daiichi Sankyo Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed Daiichi Sankyo Co Ltd's rating at "AA".Rating outlook negative.  Full Article

Daiichi Sankyo and Charleston Laboratories announce Collaboration to Develop and Commercialize Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting in the US
Wednesday, 6 Aug 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced that the parties have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone combination products.Says the products including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting (OINV).With this collaboration,Daiichi Sankyo Co., Ltd. will be the commercialization partner for CL-108 in the United States.Charleston Laboratories will be responsible for manufacturing activities for CL-108 and will receive the right to co-promote this and other hydrocodone products in the United States.  Full Article

Alfresa Holdings Corp subsidiary to acquire plant from subsidiary of Daiichi Sankyo
Thursday, 31 Jul 2014 04:00am EDT 

Alfresa Holdings Corp:Announces wholly owned subsidiary Alfresa Pharma Corporation to acquire plant based in Akita from Daiichi Sankyo Propharma Co., Ltd that wholly owned by Daiichi Sankyo.Says Daiichi Sankyo to establish a new wholly owned subsidiary to take over Akita plant related business from Daiichi Sankyo Propharma Co., Ltd, then to transfer entire stake in this subsidiary to Alfresa Pharma Corporation in April, 2015.Says to sign final contract expected in November and transaction expected effective in April, 2015.  Full Article

Daiichi Sankyo Co Ltd announces reorganization of Japanese supply chain subsidiaries
Thursday, 31 Jul 2014 03:30am EDT 

Diichi Sankyo Co Ltd:To reorganize three Japanese supply chain subsidiaries (DSPP, DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. (DSCP) and DAIICHI SANKYO LOGISTICS CO., LTD. (DSLG)) into two companies by April 2015.Says surviving two companies will be DSCP, with API production function, and DSPP, with dosage forms production and logistics function.Says Onahama and Tatebayashi API production plants currently owned by DSPP will be taken over by DSCP and DSLG will be merged into DSPP.  Full Article

Daiichi Sankyo Co Ltd to establish subsidiary and to sell subsidiary to Alfresa Pharma
Thursday, 31 Jul 2014 03:30am EDT 

Daiichi Sankyo Co Ltd:To establish new subsidiary in September to succeed Akita plant, which is currently owned by subsidiary DAIICHI SANKYO PROPHARMA.To sell the new subsidiary named TBC to Alfresa Pharma on April 1, 2015.  Full Article

Daiichi Sankyo announces resignation of chairman
Thursday, 15 May 2014 12:00am EDT 

Daiichi Sankyo Co Ltd:Says Takashi Shoda will resign from chairman of the board, on June 23.  Full Article

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

Search Stocks